


| business SciMount announces FDA approval of SMP-100's IND application for the treatment of Irritable Bowel Syndrome PR Newswire Asia |
|
CHENGDU, China May 13, 2020 /PRNewswire/ -- SciMount Pharmatech, Co. Ltd., a wholly-owned subsidiary of Xiling Lab , announces today that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for SMP-100 for the treatment of Irritable Bowel Syndrome with diarrhea (IBS-D).
Posted: 2020-05-14 14:29:00
|
If you are a broadcaster or Christian program producer you can schedule a 15 min FREE consultation with an EGR specialist to help you evaluate all possible Int'l broadcasting options.
We will call you back at a number and time of your convenience, and will gladly answer any question that you may have on how to broadcast your Christian message worldwide.